Project Grant R21AG083776
Award Date
9/15/24
Completion Date
8/31/26
Dollars Obligated
$432K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Nashville, TN 37203, USA
Similar Awards
The National Institute on Aging (NIA), under its Aging Research Federal Grant Program (CFDA 93.866), awarded a $4,622,818 Cooperative Agreement to investigate proteomic biomarkers for cognitive and brain changes prior to the onset of Alzheimer's disease and related dementias (AD/ADRD). The project will measure 7,000 proteins and established AD/ADRD biomarkers in the Lothian Birth Cohort 1936, a well-characterized longitudinal study, at ages 73, 76, 82, and 85. The research aims to identify...
The National Institute on Aging (NIA), under its Aging Research Federal Grant Program (CFDA 93.866), awarded a $154,748 Project Grant to Brigham & Women's Hospital Inc. to develop an ultrasensitive blood-based diagnostic tool for accurately detecting and monitoring Alzheimer's disease (AD). The project aims to engineer a diagnostic pipeline that leverages extracellular vesicles (EVs) and single molecule detection technology to quantify low-abundance AD protein biomarkers, particularly...
The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $472,695 project grant to 3D Bioanalytix, Inc. to develop a blood-based diagnostic test for early detection and differentiation of neurodegenerative diseases such as Alzheimer's and Parkinson's. The project leverages the company's Covalent Protein Painting (CPP) platform technology to detect and identify misfolded protein aggregates that characterize these diseases. This novel...
This Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $885,006 to Brigham & Women's Hospital Inc. to develop a smartphone-based point-of-care diagnostic system for detecting Alzheimer's disease-related biomarkers in blood plasma. The system will utilize microfluidics, nanotechnology, optical sensing, and deep learning to measure amyloid-beta, phosphorylated tau, and neurofilament light chain within 30 minutes, with the goal of creating an...
This federal Project Grant award of $307,000.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to conduct a single, highly powered study to identify memory processes that are most sensitive to the asymptomatic, preclinical stage of Alzheimer's disease (AD) pathology. The study combines a continuous report item-location associative memory task with advanced behavioral and neural modeling to estimate subtle changes in memory precision that may differentiate healthy...
This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to investigate the presence of Alzheimer's disease (AD) biomarkers in nasally exhaled breath. The $440,000 award to Northwestern University will fund research to test the hypothesis that neural proteins associated with AD, such as tau and beta-amyloid, can be detected and quantified in nasally exhaled breath samples. The 2-year project period runs from...
This $107,948 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to enhance understanding of the biological signatures that distinguish subgroups of patients with Alzheimer's disease (AD). The key goals are to: Determine if AD subtypes can be identified solely using magnetic resonance imaging (MRI)-derived features through the application of machine learning algorithms. Integrate epigenetic profiles, including small non-coding RNA expression and DNA...
This Project Grant award of $372,690 from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to discover the heterogeneous causal pathophysiology of Alzheimer's disease (AD). The project will develop new statistical methods to uncover how amyloid-beta, tau accumulation, and cognition are causally related in different AD subpopulations. The goal is to reveal optimal treatment windows and target groups for therapies that reduce amyloid-beta or...
This federal Project Grant award from the National Institute on Aging (NIA), under CFDA 93.866 Aging Research, is providing $509,038 to Ceiba Bio Inc. to develop a blood-based exercise mimetic as a potential treatment for Alzheimer's disease and related dementias. The key objectives are to: 1) identify 3 lead recombinant human GPLD1 molecules, 2) establish optimal exposure through in vivo PK profiling in aged mice, and 3) test 1 primary and 1 alternate lead GPLD1 molecule for disease...